Comparison of Bioluminescence and MR Imaging to Evaluate Orthotopic Glioma Models

Glioblastoma multiforme (GBM) (also called glioblastoma) is a fast-growing glioma that develops from star-shaped glial cells (astrocytes and oligodendrocytes) that support the health of the nerve cells within the brain. These tumors are usually highly malignant because the cells reproduce quickly and they are supported by a large network of blood vessels. GBM is the […]

CT26: Murine Colon Carcinoma

CT26 and Flow Cytometry In addition to evaluating efficacy of anti-cancer drug combinations this model has proven useful in the assessment of phenotypic changes in the immune system. To this end we have evaluated CT26 tumors for a number of fundamental tumor infiltrating leukocytes with our Attune NxT® flow cytometer. […]

Quantify T Cell Biodistribution Non-Invasively in Animal and Human Subjects

MI Bioresearch (MI) is looking for expressions of interest from companies involved in CAR-T and T Cell Receptor therapies, regarding non-invasive cell tracking in vivo.  MI is using a validated MRI platform that can be used to label T cells and detect/track cells in rodents.1  This strategy can also be implemented in NHP studies and clinical […]

GL261: Syngeneic Murine Glioma Model

GL261 is one of the most frequently used syngeneic murine glioma models available. We capitalize on our state-of-the-art imaging capabilities to further interrogate the pharmacology of this model by utilizing a GL261 cell line that expresses luciferase (GL261-luc2, Caliper Life Sciences). This allows for longitudinal, in vivo visualization of the […]

MV(4;11): A Model of Human AML (acute myeloid leukemia)

Acute myeloid leukemia (AML) is a malignant disorder of the progenitor cells in myeloid hematopoiesis and represents a genetically heterogeneous cancer. The onset of AML is thought to require cooperation between active proliferation and defects in myeloid differentiation, which often results in chromosomal translocation (Gilliland et al., 2004). The annual incidence of AML is ~1.8 per […]

Driving Translational Imaging to a Drug Industry Standard: Case Studies in Glioblastoma and Other Clinically Predictive Cancer Models

Medical imaging technologies can facilitate drug discovery, efficacy evaluation, and translation into the clinic. Now a maturing platform, molecular imaging is the catalyst for a new standard of how drug candidates are evaluated and advanced into trials. By providing clinically translatable biomarkers as an accompaniment to standard measures of response, imaging leverages and amplifies the […]